Yükleniyor... / Loading...
This study evaluates pancreatic cancer screening, using methods such as MRI and endoscopic ultrasound, in people carrying inherited (germline) mutations in the BRCA1, BRCA2, ATM, or PALB2 genes. It enrolls people with confirmed mutations in these genes who meet certain age criteria based on their family history. This non-phase study is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: Ability to provide consent and willing, and able to comply with study procedures Ability to read and speak English GROUP I: * Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation * No strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * Age \>= 50 years old at time of consent. GROUP II: * Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation * Has strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer) * Age \>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family) Exclusion Criteria: * Prior or active pancreatic cancer. * Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.